ClinicalTrials.Veeva

Menu

Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal (Epi-Asthma)

AstraZeneca logo

AstraZeneca

Status

Completed

Conditions

Asthma

Study type

Observational

Funder types

Industry
Other

Identifiers

NCT05169619
D2287R00155

Details and patient eligibility

About

This study aims to determine the prevalence of Asthma, Difficult-to-Treat and Severe Asthma in Portugal, and characterize patients to better understand their disease characteristics, treatment profile and health care resource use to improve clinical management of the disease.

Full description

Data on the epidemiology of asthma in Portugal were mainly grounded in studies using questionnaires and covering limited age groups. Studies assessing the prevalence of asthma diagnosis and of its sub-groups with more accurate methods are therefore needed This study aims to determine the prevalence of asthma, difficult-to-treat and severe asthma in Portugal, and to characterize patients to better understand their disease characteristics, treatment profile and health care resource use to improve clinical management of the disease.

We will conduct a population-based nationwide study with a multicentre stepwise approach, enrolling 7500 adult subjects, randomly selected, from the Portuguese National Health Service patients' database of 38 primary care centres:

STAGE 0 - Phone call invitation and enrolment of participants STAGE 1 - Telephone interview survey to assess respiratory symptoms. STAGE 2 - Clinical assessment, diagnostic confirmation, and patient characterization STAGE 3 - Characterization of asthma patients (sub-group) and characterization of difficult- to-treat asthma & severe asthma patients after 3 months follow up period.

Enrollment

842 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Adults =>18 years old registered in Portuguese National Health service patients' database of primary care units.
  • Give voluntary signed informed consent,
  • Ability to understand ans answer questionnaires.

Exclusion criteria

  • Participants that have a physical condition that could interfere with the study assessments or prevent the participant from adequately participating in the study (e.g. mobility problems, not able to perform spirometry,...)

Trial contacts and locations

37

Loading...

Central trial contact

AstraZeneca Clinical Study Information Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems